GLP1’s have been available in the US since 2005. This class of drugs continues to change the way that obesity and diabetes are managed today, including improvements in cardiac health, weight loss, blood pressure, and insulin sensitivity. This program will address GLP1 Agonists, mechanism of action, side effects and how to mitigate them. Case scenarios will be used to share best practices in the utilization of GLP1’s. This activity (#176872) has been approved by CDR for 1 CPEU.

Presented by:

Diana Isaacs, PharmD, BC-ADM, CDCES – Director of Education & Training in Diabetes Technology at the Cleveland Clinic Diabetes Center. Diana utilizes the latest technology and innovation to improve outcomes for people with diabetes. Isaacs has delivered advanced diabetes care through clinical services, professional organizational involvement, and scholarly activities. She has initiated many new services at her health system to help people with diabetes, including a continuous glucose monitoring shared medical appointment programs and a pharmacist run insulin dose adjustment services for post-transplant patients. She holds many leadership roles in diabetes organizations and has presented programs nationally on diabetes topics.
 

Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES is an Endocrine Nurse Practitioner and the Program Director for Diabetes Technology at University Hospitals in Cleveland, Ohio, and is a Faculty Advisor for Close Concerns. Dr. Bellini earned her bachelor’s degree in nursing from Drexel University and Family Nurse Practitioner and Doctor of Nursing Practice from D’Youville University in Buffalo, NY. Dr. Bellini holds board certifications as a family nurse practitioner and in advanced diabetes management. She has published studies on topics including the use of GLP-1 agonists in patients with Type 1 diabetes and using technology in diabetes management for both type 1 and type 2 diabetes. She has been a speaker nationally and internationally regarding diabetes management and the impact of technology on diabetes care and outcomes. 

As a faculty member for Close Concerns, Natalie works with the Close Concerns associates to bring perspective as a patient and a clinician to data and outcomes presented at conferences and earnings reports. Natalie co-hosts podcast Diabetes Dialogue: Technology, Therapeutics, & Real Word Perspectives with colleague Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, through HCPLive at https://www.hcplive.com/clinical/endocrinology.

Rachel Stahl Salzman, MS, RDN, CDN, CDCES is a Lecturer in Medicine in the Division of Endocrinology, Diabetes and Metabolism at Weill Cornell Medicine (WCM) in New York City. Rachel is passionate about empowering individuals to make sustainable lifestyle changes and leverage diabetes technology and digital health to improve their health and quality of life. In addition to her clinical practice, she coordinates New York-Presbyterian Hospital (NYPH)/WCM Diabetes Prevention Program, serves as a preceptor for the NYPH Dietetic Internship Program and contributes to interdisciplinary education.

Rachel is actively involved in leading professional societies, serving as President-Elect of the Association of Diabetes Care and Education Specialists (ADCES) Metropolitan New York Chapter and Diabetes Technology Chair of the Diabetes Dietetic Practice Group of the Academy of Nutrition and Dietetics. Rachel frequently presents at regional and national conferences and publishes on topics related to nutrition, diabetes management, and digital health. Her dedication and leadership have earned her numerous honors, including the Rising Star Award from ADCES in 2022 and Recognized Young Dietitian of the Year from the New York Academy of Nutrition and Dietetics (NYSAND) in 2016.